Patents Assigned to Pfizer
  • Purine compounds and uses thereof
    Publication number: 20040092520
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: October 20, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc.
    Inventor: David A. Griffith
  • Methods of using piperazine derivatives
    Publication number: 20040092529
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: October 16, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc
    Inventors: Laura C. Blumberg, Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, Matthew M. Hayward, Gregory D. Lundquist, Christopher S. Poss, Andrei Shavnya
  • Compositions and methods for treating conditions responsive to estrogen
    Publication number: 20040092506
    Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in treating conditions responsive to estrogen by the administration of estrogen agonists/antagonists. Conditions responsive to the compositions and methods include rheumatoid arthritis, colon cancer, tissue wounds, skin wrinkles and cataracts. The compositions are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.
    Type: Application
    Filed: August 29, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc
    Inventors: David D. Thompson, Andrew G. Lee, Wesley W. Day, Robert L. Rosati
  • Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
    Publication number: 20040092547
    Abstract: The present invention relates to novel alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Application
    Filed: August 27, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc
    Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
  • 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
    Publication number: 20040092550
    Abstract: Cholesteryl ster transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain oth r plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Application
    Filed: June 27, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc.
    Inventors: Michael P. DeNinno, George T. Magnus-Aryitey, Roger B. Ruggeri, Ronald T. Wester
  • Substituted pyridines via boronic acid coupling
    Publication number: 20040092741
    Abstract: The invention relates to a convergent process for preparing a compound of the formula (V), wherein R1 is attached at the 2 or 3 position of the benzene ring, R2 is attached at the 5 or 6 position and R1, R2 and G are as defined herein, in which an aryl boronic acid is coupled with an amine protected halo-substituted-2-aminopyridine using a palladium coupling agent. Compounds of formula V are useful as nitric oxide synthase (NOS) inhibitors in a mammal.
    Type: Application
    Filed: October 1, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc
    Inventors: Stephane Caron, Jolanta Nowakowski
  • Adjuvants for use in vaccines
    Patent number: 6733754
    Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: May 11, 2004
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: David S. Roberts, Leroy A. Swearingin, Don A. Dearwester
  • Process for the production of quinazolines
    Patent number: 6734303
    Abstract: The invention provides a process for the production of a compound of formula (A) or a pharmaceutically acceptable salt or solvate thereof: which comprises condensing a compound of formula (B) with a compound of formula (C): Compounds of formula (A) are useful in the treatment of benign prostatic hyperplasia.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: May 11, 2004
    Assignee: Pfizer Inc.
    Inventors: Jens Bertil Ahman, Paul Blaise Hodgson, Sarah Jane Lewandowski, Robert Walton
  • Treatments for obesity and methods for identifiying compounds useful for treating obesity
    Patent number: 6734175
    Abstract: The present invention provides a method of treating obesity, sexual dysfunction (including erectile dysfunction), diabetes, insulin resistance, hyperinsulinemia, Syndrome X, adrenal dysfunction, hypertension, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia, hypertriglyceridemia, or substance abuse, the method comprising the step of administering to a patent having or at risk of having one of the above-mentioned diseases a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: May 11, 2004
    Assignee: Pfizer Inc.
    Inventors: John R. Hadcock, Andrew G. Swick
  • Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3,- dihydroxybutanedioate salts and method of production
    Patent number: 6734308
    Abstract: The invention relates to crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate salts having the formula shown below: and to pharmaceutical compositions containing the above compound, methods of treating hyperproliferative diseases, such as cancers, in mammals, especially humans by administering the above compound, and to methods of preparing the crystal forms of the above compound and related compounds.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: May 11, 2004
    Assignee: Pfizer Inc
    Inventors: Joseph P. Lyssikatos, Derek L. Tickner, Linda S. Newton, Zheng J. Li, Clifford N. Meltz
  • Compounds for the treatment of female sexual dysfunction
    Patent number: 6734186
    Abstract: A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: May 11, 2004
    Assignee: Pfizer Inc.
    Inventors: Graham Nigel Maw, Christopher Peter Wayman
  • N-benzenesulfonyl L-proline compounds as bradykinin antagonists
    Patent number: 6734306
    Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein X1 and X2 are halo; R1 and R2 are independently hydrogen or C1-4 alkyl; R3 and R4 are each hydrogen or halo; and R5 is (a) —C3-9 diazacycloalkyl optionally substituted with C5-11 azabicycloalkyl; (b) —C3-9 azacycloalkyl-NH—(C5-11 azabicycloalkyl optionally substituted with C1-4 alkyl); (c) —NH—C1-3 alkyl-C(O)—C5-11 diazabicycloalkyl; (d) —NH—C1-3 alkyl-C(O)—NH—C5-11 azabicycloalkyl, the C5-11 azabicycloalkyl being optionally substituted with C1-4 alkyl; (e) —C3-9 azacycloalkyl optionally substituted with C3-9 azacycloalkyl; or (f) —NH—C1-5 alkyl-NH—C(O)—C4-9 cycloalkyl-NH2. These compounds are useful for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: May 11, 2004
    Assignee: Pfizer, Inc.
    Inventors: Yasuhiro Katsu, Makoto Kawai, Hiroki Koike, Seiji Nukui
  • Triamide-substituted heterobicyclic compounds
    Publication number: 20040087625
    Abstract: The invention relates to triamide MTP/ApoB inhibitors of the formula 1 1
    Type: Application
    Filed: August 13, 2003
    Publication date: May 6, 2004
    Applicant: Pfizer Inc
    Inventors: Peter Bertinato, Brian S. Bronk, Alan E. Blize, Hengmiao Cheng, Jin Li, Hiep Huatan, Clive Mason
  • Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture
    Publication number: 20040087797
    Abstract: This invention relates to dihydro-furan-2-one derivatives, their intermediates and methods of manufacture.
    Type: Application
    Filed: October 16, 2003
    Publication date: May 6, 2004
    Applicant: Pfizer Inc
    Inventor: Zhengong B. Li
  • Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
    Publication number: 20040087615
    Abstract: The present invention relates to novel cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Application
    Filed: August 27, 2003
    Publication date: May 6, 2004
    Applicant: Pfizer Inc
    Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
  • cGMP-PDE inhibitors for the treatment of erectile dysfunction
    Publication number: 20040087599
    Abstract: Pyrazolopyrimidine compounds which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
    Type: Application
    Filed: October 27, 2003
    Publication date: May 6, 2004
    Applicant: Pfizer Inc
    Inventors: Simon Fraser Campbell, Alexander Roderick Mackenzie, Anthony Wood
  • Methods of using CCR1 antagonists as immunomodulatory agents
    Publication number: 20040087571
    Abstract: The present invention relates to methods of using CCR1 antagonists as immunomodulatory agents.
    Type: Application
    Filed: October 16, 2003
    Publication date: May 6, 2004
    Applicant: Pfizer Inc
    Inventors: Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, John C. Kath, Christopher S. Poss
  • Process for producing crystalline atorvastatin calcium
    Patent number: 6730797
    Abstract: A factory scale process for producing crystalline atorvastatin calcium includes the step of drying the isolated product in a vacuum pan dryer. The vacuum pan dryer has an agitator which is continuously rotated at a speed of approximately 1 rpm. High quality material is routinely and consistently produced with reduced cycle time.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: May 4, 2004
    Assignee: Pfizer Science and Technology Ireland Limited
    Inventors: John O'Connell, William Tully, Evelyn Madigan
  • Process for the preparation of pyrazolopyrimidinones
    Patent number: 6730786
    Abstract: There is provided a process for the production a compound of general formula I: wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the dehydrogenation of a compound of general formula II,
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: May 4, 2004
    Assignee: Pfizer Inc
    Inventors: Mark Edward Bunnage, Philip Charles Levett, Nicholas Murray Thomson
  • Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
    Patent number: 6730674
    Abstract: This invention relates to novel sulfonyl pyridazinone compounds of the formula: wherein R1, R2, X, and Y are defined herein, which are useful as aldose reductase inhibitors in the treatment or prevention of certain complications arising from diabetes mellitus, pharmaceutical compositions comprising the sulfonyl pyridazinone, pharmaceutical compositions comprising a combination of the sulfonyl pyridazinone together with a second pharmaceutical agent, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds in combination with a second pharmaceutical agent and compounds useful as intermediates for preparing the sulfonyl pyridazinone compounds of this invention.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: May 4, 2004
    Assignee: Pfizer Inc
    Inventors: William H. Martin, Banavara L. Mylari